Our present study demonstrated that CX-4945 effectively attenuated the tumor-promoting effects of TET1 in cancer cells under hypoxia, providing a molecular explanation for the anti-cancer effect of CK2 inhibitors and further supporting their therapeutic potential in solid cancers, particularly those with high TET1 expression. Here, TET1 is linked to cancer.